The MOIR-ACTOME project focuses on studying the molecular causes of insulin resistance and related diseases such as obesity, type 2 diabetes, gestational diabetes, and metabolic syndrome. It aims to identify new molecular factors involved in insulin resistance, understand how different tissues interact, and search for biomarkers in biological fluids. The project seeks a better understanding of this metabolic defect, which is present in diseases like obesity and diabetes, through a communication network between organs mediated by hormones, inflammatory molecules, RNAs, and extracellular vesicles. The goal is to find new targets for treatments, biomarkers for early detection, and preventive methods, addressing the need for pharmacological treatments beyond lifestyle changes.

The MOIR-ACTOME consortium implements a range of advanced research methodologies, including in vitro studies in cell cultures, in vivo assays using animal models, and clinical applications. Its expertise extends to collaborations with various academic and corporate entities nationally and internationally, fostering the integration of multidisciplinary approaches and knowledge transfer between the academic sector and industry. Additionally, the consortium establishes partnerships with high-level hospitals in the Community of Madrid to address the translational approach of human biology and pathophysiology. A notable collaboration is carried out with ALCER-Madrid, a patient association, to facilitate the incorporation of patient perspectives in research and promote the direct application of scientific advances in improving the care and treatment of patients affected by the studied conditions.